Alla studier
Aktiv men inte rekryterandeFAS1, FAS2INTERVENTIONELL

A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

This research study is looking at a new treatment called UX701, a gene therapy, for adults who have Wilson disease. Wilson disease is a condition where the body has trouble getting rid of extra copper. The main goals of this study are to check if UX701 is safe, to figure out what dose works best without too many side effects, and to see how well it helps control copper levels in the body. The study will happen in stages, starting with a small group to find a safe and effective dose, then a larger group where some people will get UX701 and others will continue with their usual care. Researchers will follow participants for at least five years to understand the long-term effects.

Överblick

Status
Aktiv men inte rekryterande
Fas
FAS1, FAS2
Sponsor
Ultragenyx Pharmaceutical Inc
Inskrivningsmål
82
Starta
27 Sep 2021
Beräknad slutförande
01 Mar 2034

Vad handlar denna studie om?

This study is investigating a new treatment called UX701, which is a "gene therapy" designed for adults living with Wilson disease. Wilson disease is a condition you're born with where your body doesn't handle copper properly, leading to too much copper building up in important organs like the liver and brain. Current treatments help manage the copper, but this new therapy aims to address the root cause.

The main reasons for doing this study are to make sure UX701 is safe for people to use, to work out the most effective and safe amount (dose) of the treatment, and to see if it genuinely helps the body to control copper levels better. Researchers want to compare UX701 with the standard care that people usually receive for Wilson disease, which includes medicines like penicillamine or trientine, and zinc therapy.

The study will take place in different stages. First, a small group will help find a safe dose and see initial effects. Then, a larger group will be involved where some receive UX701 and others continue with their usual treatment, so doctors can clearly see the differences. Finally, everyone who receives UX701 will be followed for at least five years to understand its long-term benefits and safety. This is an important step towards potentially offering a new way to manage Wilson disease.

Viktiga punkter

  • This study is for adults with Wilson disease.
  • It's testing a new gene therapy called UX701.
  • The goal is to find a safe and effective dose to help manage copper levels.
  • It involves regular check-ups, blood tests, and long-term monitoring.
  • Participation includes receiving other medications alongside the main treatment.
  • You can choose to leave the study at any time.

Vem kan vara berättigad?

To join this study, you must be at least 18 years old and have a confirmed diagnosis of Wilson disease, usually proven by genetic tests. You should also be managing your Wilson disease with regular copper-removing medicines or zinc therapy for at least two months without any recent changes to your medication or diet. You'll also need to be willing to follow all the study instructions, including regular blood tests and providing urine samples.

There are also reasons why someone might not be able to join. For example, if you've already had a liver transplant or if your liver disease is very severe. Other reasons could include having serious heart or kidney problems, certain mental health conditions, or if you've had a strong allergic reaction to similar medicines in the past. If you have a history of not consistently taking your Wilson disease medication, or if you've been in another similar gene therapy study, you might also not be eligible.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du 18 år eller äldre?
  2. Do you have a confirmed diagnosis of Wilson disease?
  3. Have you been on stable Wilson disease medication for at least 2 months?
  4. Are you willing to attend regular appointments and provide samples?
  5. Have you NOT had a liver transplant?
  6. Do you have mild to no major liver or kidney problems?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you will receive either UX701 or continue with your standard care. Everyone who receives UX701 will also be given other medications to help prepare your body for the treatment and to prevent side effects. These include medicines called premedication, corticosteroids (like a type of steroid), and other treatments to help your immune system.

Throughout the study, you'll have regular visits to the clinic. These visits will involve various checks, including frequent blood tests, collecting all your urine over a 24-hour period, and completing questionnaires about how you're feeling and your quality of life. The study involves a long-term follow-up period, meaning that after you receive the treatment, doctors will continue to monitor your health and how well the treatment is working for at least five years. The total time you'll be involved in the study will vary, but expect a commitment over several years due to these follow-up checks.

Potentiella risker och fördelar

Participating in a study like this might offer the potential benefit of trying a new treatment that could potentially improve how your body handles copper, possibly leading to better management of your Wilson disease. However, as with any new treatment, there are potential risks and side effects. These could range from reactions to the study medication to other health changes that doctors will closely monitor. You will be told about all known risks before you decide to join. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Platser (16)

  • University of California Los Angeles
    Verifierat postnummer
    Los Angeles, USA
  • Stanford Universitet
    Verifierat postnummer
    Redwood City, USA
  • University of California Davis
    Verifierat postnummer
    Sacramento, USA
  • Northwestern University
    Verifierat postnummer
    Chicago, USA
  • Indiana Universitet
    Verifierat postnummer
    Indianapolis, USA
  • Massachusetts General Hospital
    Verifierat postnummer
    Boston, USA
  • University of Michigan
    Verifierat postnummer
    Ann Arbor, USA
  • Duke University Medical Center
    Verifierat postnummer
    Durham, USA
  • University Hospitals Cleveland Medical Center
    Verifierat postnummer
    Cleveland, USA
  • Vanderbilt University Medical Center
    Verifierat postnummer
    Nashville, USA
  • University of Utah
    Verifierat postnummer
    Salt Lake City, USA
  • Seattle Barnsjukhus
    Verifierat postnummer
    Seattle, USA

Vanliga frågor

Vad är genterapi?

Gene therapy aims to fix faulty genes that cause diseases like Wilson disease by introducing a new, working gene into your body.

Will I have to stop my current Wilson disease medication?

The study design involves a comparison, so some participants may continue their standard medication while others receive UX701. Your doctor will explain this carefully.

What kind of monitoring will I need?

You'll have regular clinic visits, blood tests, urine collection, and questionnaires to check your health and how the treatment is working.

Hur länge kommer jag att vara med i studien?

The study involves a long-term follow-up, meaning you'll be monitored for at least five years after receiving UX701 to see its long-term effects.

What if I experience side effects?

The study team will closely monitor you for any side effects and will provide care and support. Your safety is their top priority.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.